BEIJING HOTGEN BIOTECH CO. LTD.
Beijing Hotgen Biotech Co., Ltd. (“Hotgen Biotech”) was founded in 2005 and listed on the STAR Market in 2019 (Stock Code: 688068). Its Institute of Future Technology develops nucleic acid, antibody, and biotech health products. Hotgen created the world’s first antibody for emergency myocardial infarction, approved in China and the US with FDA Fast Track. It offers UPT POCT devices, MQ60 and C800 analyzers covering 100+ parameters in thyroid, cardiovascular, oncology, and DOA testing. With 600+ international certifications and offices in Europe, India, and the Americas, Hotgen is committed to advancing biotechnology and improving human health.
